TMDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TransMedics Group Inc (TMDX) is not a strong buy for a beginner, long-term investor at this moment. While the stock has shown positive price momentum recently, the lack of strong proprietary trading signals, insider selling activity, and mixed analyst ratings suggest a cautious approach. The investor should wait for clearer growth signals or a more favorable entry point.
The MACD is positively expanding with a histogram of 1.881, indicating bullish momentum. RSI is at 71.41, which is neutral but nearing overbought territory. Moving averages are converging, signaling indecision. Key resistance levels are at 79.035 and 81.815, while support levels are at 70.035 and 67.255.
The stock has shown a strong regular market change of 7.61% and a pre-market increase of 2.43%. Analysts like Piper Sandler and TD Cowen maintain a positive long-term outlook despite recent challenges. Management's confidence in full-year revenue guidance is a positive sign.
Insiders are selling heavily, with a 186.38% increase in selling activity over the last month. Analysts have lowered price targets significantly, citing competition concerns, trial enrollment challenges, and missed Q1 revenue and earnings estimates. Oppenheimer downgraded the stock to Perform, citing exhaustion defending the name.
No financial data available for analysis. However, Q1 results missed consensus estimates, and analysts have expressed concerns about near-term growth.
Analysts are mixed on the stock. While some maintain Buy or Outperform ratings with reduced price targets (e.g., Needham, Piper Sandler, Baird), others like Stifel and Oppenheimer have downgraded or maintained Hold ratings due to competition concerns and missed earnings.
